Abatacept
- Generic Name
- Abatacept
- Brand Names
- Orencia
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 332348-12-6
- Unique Ingredient Identifier
- 7D0YB67S97
- Background
Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of tw...
- Indication
Abatacept is indicated in adult patients for the treatment of moderately-to-severely active rheumatoid arthritis and for the treatment of active psoriatic arthritis. In patients two years of age and older, abatacept is also indicated for the treatment of moderately-to-severely active juvenile idiopathic arthritis.
...
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), Moderate to Severe Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Polyarticular juvenile rheumatoid arthritis, chronic or unspecified, Psoriatic Arthritis
- Associated Therapies
- -
Abatacept Conversion in Kidney Transplantation
- Conditions
- Interventions
- First Posted Date
- 2021-07-08
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- Emory University
- Target Recruit Count
- 86
- Registration Number
- NCT04955366
- Locations
- 🇺🇸
Emory University Hospital (EUH), Atlanta, Georgia, United States
An Exploratory Study on the Efficacy and Safety of Abatacept in the Treatment of Refractory Dermatomyositis
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2021-07-01
- Target Recruit Count
- 20
- Registration Number
- NCT04946669
- Locations
- 🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
- Conditions
- Interventions
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 38
- Registration Number
- NCT04925375
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸University of South Florida, Tampa, Florida, United States
🇺🇸Lahey Hospital and Medical Center, Burlington, Massachusetts, United States
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
- Conditions
- Interventions
- First Posted Date
- 2021-06-02
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 338
- Registration Number
- NCT04909801
- Locations
- 🇮🇹
Local Institution - 0083, Catania, Italy
🇮🇹Local Institution - 0077, Pavia, Italy
🇺🇸Local Institution - 0036, Fullerton, California, United States
Adjuvant Treatment With Abatacept to Promote Remission During Peanut Oral Immunotherapy
- Conditions
- Interventions
- First Posted Date
- 2021-05-04
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Philippe Bégin
- Target Recruit Count
- 14
- Registration Number
- NCT04872218
- Locations
- 🇨🇦
CHU Sainte-Justine, Montréal, Quebec, Canada
Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis
- Conditions
- Interventions
- First Posted Date
- 2021-05-04
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 42
- Registration Number
- NCT04871191
- Locations
- 🇫🇷
Hôpital de la Croix Saint Simon, Paris, France
Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 270
- Registration Number
- NCT04610476
- Locations
- 🇩🇪
Universitätsklinikum Erlangen, Erlangen, Bavaria, Germany
Immune Modulators for Treating COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Daniel Benjamin
- Target Recruit Count
- 1971
- Registration Number
- NCT04593940
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸University of Washington Medical Center, Seattle, Washington, United States
🇺🇸University of Arkansas Medical Sciences, Little Rock, Arkansas, United States
Rituximab and Abatacept Effectiveness in Differential Treatment of Interstitial Lymphocytic Lung Disease in Children With Primary Immunodeficiencies.
- Conditions
- Interventions
- First Posted Date
- 2020-10-01
- Last Posted Date
- 2020-10-01
- Target Recruit Count
- 30
- Registration Number
- NCT04572620
- Locations
- 🇷🇺
Dmitry Rogachev National Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Tocilizumab vs Abatacept
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2021-11-16
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 30432
- Registration Number
- NCT04529863
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.